Thalidomide in Multiple Myeloma: current status and future prospects
References
Badros, A., Zangari, M., Bodenner, D., Siegel, E., Spoon, D., Toor, A., Desikan, R., Arnold, E., Anaissie, E., Zeldis, J., Tricot, G. & Barlogie, B. (2000) [4973] Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide. Blood; 96 (Suppl 2): 285b [no abstract available]
Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., Badros, A., Zangari, M., Anaissie, E., Epstein, J., Shaughnessy, J., Ayers, D., Spoon, D. & Tricot, G. (2001a) Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood, 98, 492-494.
Barlogie, B., Zangari, M., Spencer, T., Fassas, A., Anaissie, E., Badros, A., Cromer, J. & Tricot, G. (2001b) Thalidomide in the management of multiple myeloma. Seminars in Hematology, 38, 250-259.
Bellamy, W.T., Richter, L., Frutiger, Y. & Grogan, T.M. (1999) Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Research, 59, 728-733.
Bennett, C.L., Schumok, G.T., Kwaan, H.C. & Raisch, D.W. (2001) [3581] High Incidence of Thalidomide-Associated Deep Vein Thrombosis and Pulmonary Emboli when Chemotherapy Is also Administered. Blood, 98, (Suppl. 1), 863a. [no abstract available]
Clark, P. & Walker, I.D. (2001) The Phenomenon known as acquired activated protein C resistance. British Journal of Haematology, 115, 767-773. [no abstract available]
Coleman, M., Leonard, J.P., Pekle, K., Lyons, L. & Michaeli, J. (2001) [P211] Biaxin, Low-Dose Thalidomide, and dexamethasone [BLT-D] are highly active in Waldenstrom's Macroglobulinemia and Multiple Myeloma. VIIIth International Myeloma Workshop, Banff, Alberta, Canada 224 [no abstract available]
Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L.M., Ocampo, C.J., Patterson, R.T., Stirling, D.I. & Kaplan, G. (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology, 163, 380-386.
D'Amato, R.J., Loughnan, M.S., Flynn, E. & Folkman, J. (1994) Thalidomide is an inhibitor of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 91, 4082-4085.
Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S.P., Richardson, P.G., Schlossman, R.L., Morgan, G.J., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2001) Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210-216.
Dimopoulos, M., Panayiotidis, P., Grigoraki, V., Poziopoulos, C., Xilouri, I., Kiamouris, C., Tassidou, A., Gika, D., Stefanoudaki, K., Anagnostopoulos, N. & Anagnostou, D. (2001) [692] Oral Hyperfractionated Cyclophosphamide and Intermittent Thalidomide-Dexamethasone for Previously Treated Patients with Multiple Myeloma. Blood, 98 (Suppl. 1): 164a. [no abstract available]
Durie, B.G.M. & Stepan, D.E. (2001) [688] Low Dose Thalidomide Alone and in Combination: Long Term Follow-Up. Blood, 98 (Suppl. 1): 163a. [no abstract available]
Folkman, J. (1974) Tumor angiogenesis. Advances in Cancer Research, 19, 331-358. [no abstract available]
Geitz, H., Handt, S. & Zwingenberger, K. (1996) Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 31, 213-221.
Grosbois, B., Bellissant, E., Moreau, P., Attal, M. & Zerbib, R. (2001) [689] Thalidomide (Thal) in the Treatment of Advanced Multiple Myeloma (MM). A Prospective Study of 120 Patients. Blood, 98 (Suppl. 1): 163a. [no abstract available]
Haslett, P.A., Corral, L.G., Albert, M. & Kaplan, G. (1998) Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset. Journal of Experimental Medicine, 187, 1885-1892.
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., Treon, S.P., Lin, B., Schlossman, R.L., Richardson, P., Muller, G., Stirling, D.I. & Anderson, K.C. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943-2950.
Holmgren, L., O'Reilly, M.S. & Folkman, J. (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine, 1, 149-153.
Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. & Malm, C. (2000) Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. British Journal of Haematology, 109, 89-96.
Kropff, M.H., Innig, G., Mitterer, M., Straka, C., Ostermann, H., Koch, W.E. & Kienast, J. (2000) [725] Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma. Blood, 96 (Suppl 1) 168a. [no abstract available]
Lentzsch, S., Podar, K., Davies, F.E., Hideshima, T., Tai, Y.T., Chauhan, D., Lin, B.K., Treon, S.P., Gupta, D., Mitsiades, C., Mitsiades, N., Hayashi, T., Muller, G.W., Stirling, D.I. & Anderson, K.C. (2000) [2486] Immunomodulatory derivatives (IMiDs) of thalidomide (Thal) inhibit the proliferation of multiple myeloma (MM) cell lines and block VEGF-induced activation of the MAPK-pathway. Blood, 96 (Suppl 1) 579a. [no abstract available]
Moreira, A.L., Sampaio, E.P., Zmuidzinas, A., Frindt, P., Smith, K.A. & Kaplan, G. (1993) Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. Journal of Experimental Medicine, 177, 1675-1680.
Moehler, T.M., Neben, K., Hawighorst, H., Egerer, G., van Kaick, G., Ho, A.D. & Goldschmidt, H. (2000) Thalidomide plus CED chemotherapy as salvage therapy in poor prognosis multiple myeloma. Blood, 96 Suppl 2: 290b. [no abstract available]
Munshi, N., Desikan, R., Anaissie, E., Zangari, M., Badros, A., Lim, S., Toor, A., Morris, C., Eddlemon, P., Ayers, D., Robertson, P. & Barlogie, B. (1999) [2577] Peripheral blood stem cell collection (PBSC) after CAD + G-CSF as part of total therapy II in newly diagnosed multiple myeloma (MM): influence of thalidomide (Thal) administration. Blood, 94 (Suppl 1): 578a. [no abstract available]
Neben, K., Moehler, T., Kraemer, A., Benner, A., Egerer, G., Ho, A. & Goldschimdt, H. (2001) Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion. British Journal of Haematology, 115, 605-608.
Oakervee, H.E., Gupta, V., Smith, M.L., Taussig, D.C., Syndercombe-Court, Y.D., Rohatiner, A.Z., Lister, T.A. & Cavenagh, J.D. (2001) [152] Response to thalidomide can be predicted by paraprotein quantitation 14 days after initiating therapy. British Journal of Haematology, 113, (Suppl. 1) 40. [no abstract available]
Oakervee, H., Brownell, A., Cervi, P., Grant, I., Rahemtulla, A., Child, A., Lloyd, L., Samson, D. & Cavenagh, J.D. (2002a) [185] A study of the safety and efficacy of thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) in the treatment of younger patients with multiple myeloma: A UK Myeloma Forum Pilot Study. British Journal of Haematology, 117 (Suppl 1) 65. [no abstract available]
Oakervee, H., Baugh, H., Boots, M., Olujohungbe, A., Smith, S., Williams, c., McBride, N., Child, A., Samson, D. & Cavenagh, J. (2002b) [189] A study of the safety and efficacy of oral Melphalan, prednisolone and Thalidomide (MPT) in the treatment of multiple myeloma: A UK Myeloma Forum Pilot Study. British Journal of Haematology, 117 (Suppl 1) 66. [no abstract available]
Osman, K., Comenzo, R. & Rajkumar, S.V. (2001) Deep venous thrombosis and thalidomide therapy for multiple myeloma. New England Journal of Medicine, 344, 1951-1952. [no abstract available]
Palumbo, A., Giaccone, L., Bringhen, S., Cavallo, F., Falco, P., Rus, C., Bertola, A., Pileri, A. & Boccadoro, M. (2001) [683] Low Dose Thalidomide and Dexamethasone Are as Effective as Oral Melphalan and Prednisone in Refractory and Relapsed Myeloma Patients. Blood, 98 (Suppl. 1): 162a. [no abstract available]
Parman, T., Wiley, M.J. & Wells, P.G. (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nature Medicine, 5, 582-585.
Payvandi, F., Wu, L., Gupta, D., Hideshima, T., Haley, M., Muller, G., Chen, R. & Anderson, K.C. (2000) [2487] Effects of a thalidomide analog on binding activity of transcription factors and cell cycle progression of multiple myeloma cell lines. Blood, 96 (Suppl 1) 579a. [no abstract available]
Powell, R.J. & Gardner-Medwin, J.M. (1994) Guideline for the clinical use and dispensing of thalidomide. Postgraduate Medical Journal, 70, 901-904. [no abstract available]
Rajkumar, S.V., Leong, T., Roche, P.C., Fonseca, R., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Kyle, R.A., Gertz, M.A. & Greipp, P.R. (2000a) Prognostic value of bone marrow angiogenesis in multiple myeloma. Clinical Cancer Research, 6, 3111-3116.
Rajkumar, S.V., Gertz, M.A. & Witzig, T.E. (2000b) Life - Threatening Toxic Epidermal Necrolysis with Thalidomide Therapy for Myeloma. New England Journal of Medicine, 343, 972-973. [no abstract available]
Rajkumar, S.V., Dispenzieri, A., Lacy, M., Geyer, S., Iturria, N., Fonseca, R., Hayman, S.R., Lust, J.A., Kyle, R., Greipp, P.R., Gertz, M.A. & Witzig, T.E. (2001a) [685] Response Rate and Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma (MM). Blood, 98 (Suppl. 1): 162a. [no abstract available]
Rajkumar, S.V., Dispenzieri A., Fonseca R., Lacy M.Q., Geyer S., Lust J.A., Kyle R.A., Greipp P.R., Gertz M.A., Witzig T.E. (2001b) Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia, 15, 12741-1276
Rajkumar, S.V., Hayman, S.R., Gertz, M.A., Dispenzieri, A., Lacy, M., Greipp, P.R., Geyer, S., Iturria, N., Fonseca, R., Lust, J.A., Kyle, R. & Witzig, T.E. (2001c) [3525] Combination Therapy with Thalidomide Plus Dexamethasone (THAL/DEX) for Newly Diagnosed Myeloma (MM). Blood, 98 (Suppl. 1): 849a. [no abstract available]
Richardson, P.G., Schlossman, R.L., Hideshima, T., Davies, F., LeBlanc, R., Catley, L., Doss, D., Kelly, K. A., McKenney, M., Mechlowicz, J., Freeman, A., Deocampo, R., Rich, R., Ryoo, J., Chauhan, D., Munshi, N., Weller, E., Thomas, S., Zeldis, J. & Anderson, K.C. (2001) [3225] A Phase 1 Study of Oral CC5013, an Immunomodulatory Thalidomide (Thal) Derivative, in Patients with Relapsed and Refractory Multiple Myeloma (MM). Blood, 98 (Suppl. 1): 775a. [no abstract available]
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeddis, J. & Barlogie, B. (1999) Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565-1571.
Tosi, P., Zamagni, E., Cellini, C., Cangini, D., Tura, S., Baccarani, M. & Cavo, M (2001). [687] Rapid Response and Early Relapse after Thalidomide Plus Dexamethasone Salvage Therapy in Patients with Advanced Relapsed and Refractory Multiple Myeloma. Blood, 98 (Suppl. 1): 163a. [no abstract available]
Tricot, G., Siegel, E., Langmaid, C., Munshi, N., Anaissie, E., Fassas, A., Desikan, R., Badros, A., Zangari, M. & Barlogie, B. (2001) [3531] Angiochemotherapy (ACT) for Multiple Myeloma (MM) with DT-PACE Results in a High Response Rate, but in Contrast to Tandem Transplants with Melphalan Does Not Affect Durable Disease Control. Blood, 98 (Suppl. 1): 850a. [no abstract available]
Turk, B.E., Jiang, H. & Liu, J.O. (1996) Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proceedings of the National Academy of Sciences of the United States of America, 93, 7552-7556.
Vacca, A., Ribatti, D., Roncali, L., Ranieri, G., Serio, G., Silvestris, F. & Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503-508.
Vacca, A., Ribatti, D., Presta, M., Minischetti, M., Iurlaro, M., Ria, R., Albini, A., Bussolino, F. & Dammacco, F. (1999) Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood, 93, 3064-3073.
Weber, D.M., Gavino, M., Delasalle, K., Rankin, K., Giralt, S. & Alexanian, R. (1999) [2686] Thalidomide alone or with dexamethasone for multiple myeloma. Blood, 94 (Suppl 1) 604a. [no abstract available]
Weber, D.M., Rankin, K., Delasalle, K., Gavino, M. and Alexanian, R. (2001) Thalidomide Alone and in Combination for Previously Untreated Myeloma. VIIIth International Myeloma Workshop, Banff, Alberta, Canada 109. [no abstract available]
Wechalekar, A.D., Sutton, D., Voralia, M., Stewart, A.K. & Chen, C.I. (2001) [684] Intermediate Dose Thalidomide (200mg Daily) Has Comparable Efficacy and Less Toxicity Than Higher Doses in Relapsed Multiple Myeloma. Blood, 98 (Suppl. 1): 162a. [no abstract available]
Zangari, M., Anaissie, E., Desikan, R., Badros, A., Morris, C., Munshi, N., Gopal, A.V., Fink, L., Spoon, D., Tricot, G. & Barlogie, B. (2000) [5024] Thalidomide-induced hypercoaguability in multiple myeloma (MM). Blood, 96 Suppl 2: 296b. [no abstract available]
Zangari, M., Tricot, G., Zeldis, J., Eddlemon, P., Saghafifar, F. & Barlogie, B. (2001a) [3226] Results of Phase I Study of CC-5013 for the Treatment of Multiple Myeloma (MM) Patients Who Relapse after High Dose Chemotherapy (HDCT). Blood, 98 (Suppl. 1): 775a. [no abstract available]
Zangari, M., Anaissie, E., Barlogie, B., Badros, A., Desikan, R., Gopal, A.V., Morris, C., Toor, A., Siegel, E., Fink, L. & Tricot, G. (2001b) Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood, 98, 1614-1615.
Zangari, M., Siegel, E., Anaissie, E., Saghafifar, F., Morris, C., Fink, L., Barlogie, B. & Tricot, G. (2001c) [681] Risk Factors for Deep Vein Thrombosis (DVT) in a Large Group of Myeloma Patients (Pts) Treated with Thalidomide (Thal): The Arkansas Experience. Blood, 98 (Suppl. 1): 161a. [no abstract available]